Get the Stockscreener App
1.30
2.26%
-0.03
Pacific Biosciences Of California Inc stock is traded at $1.30, with a volume of 6.29M.
It is down -2.26% in the last 24 hours and down -5.11% over the past month.
Pacific Biosciences of California Inc is a biotechnology company focused on designing, developing, and manufacturing sequencing solutions that enable scientists and clinical researchers to improve their understanding of the genome and ultimately, resolve genetically complex problems. It operates in, one reportable segment: the development, manufacturing, and marketing of an integrated platform for genetic analysis. The majority of the company's revenue is derived from Americas, followed by Asia-Pacific and Europe Middle East, and Africa.
See More
Previous Close:
$1.33
Open:
$1.33
24h Volume:
6.29M
Relative Volume:
0.69
Market Cap:
$390.48M
Revenue:
$188.87M
Net Income/Loss:
$-400.38M
P/E Ratio:
-0.8667
EPS:
-1.5
Net Cash Flow:
$-260.90M
1W Performance:
+7.44%
1M Performance:
-5.11%
6M Performance:
-26.55%
1Y Performance:
-18.75%
1-Day Range:
$1.25
$1.35
1-Week Range:
$1.21
$1.36
52-Week Range:
$0.8511
$2.72
Pacific Biosciences Of California Inc Stock (PACB) Company Profile
Name
Pacific Biosciences Of California Inc
Sector
Industry
Phone
650-521-8000
Address
1305 O'BRIEN DRIVE, MENLO PARK, CA
Compare PACB with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PACB
Pacific Biosciences Of California Inc
|
1.30 | 393.49M | 188.87M | -400.38M | -260.90M | -1.50 |
|
ABT
Abbott Laboratories
|
131.25 | 229.31B | 43.11B | 13.94B | 6.78B | 7.98 |
|
BSX
Boston Scientific Corp
|
103.75 | 152.87B | 18.49B | 2.50B | 3.49B | 1.68 |
|
SYK
Stryker Corp
|
389.94 | 146.01B | 23.82B | 2.92B | 4.02B | 7.55 |
|
MDT
Medtronic Plc
|
89.90 | 119.18B | 33.54B | 4.69B | 5.19B | 3.62 |
|
EW
Edwards Lifesciences Corp
|
78.93 | 45.95B | 5.69B | 1.41B | 577.90M | 6.95 |
Pacific Biosciences Of California Inc Stock (PACB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-11-24 | Downgrade | UBS | Buy → Neutral |
| Jun-03-24 | Resumed | Jefferies | Buy |
| Apr-22-24 | Downgrade | JP Morgan | Overweight → Neutral |
| Apr-18-24 | Downgrade | Goldman | Buy → Neutral |
| Dec-14-23 | Initiated | Guggenheim | Neutral |
| Dec-14-23 | Initiated | Stephens | Overweight |
| Dec-13-23 | Initiated | Wolfe Research | Peer Perform |
| Nov-17-23 | Upgrade | UBS | Neutral → Buy |
| Oct-31-23 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Sep-28-23 | Initiated | Bernstein | Outperform |
| Jul-05-23 | Resumed | JP Morgan | Overweight |
| Jun-30-23 | Initiated | Goldman | Buy |
| May-10-23 | Initiated | Barclays | Equal Weight |
| Mar-31-23 | Upgrade | TD Cowen | Market Perform → Outperform |
| Feb-02-23 | Initiated | UBS | Neutral |
| Jan-20-23 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Jan-05-23 | Initiated | Scotiabank | Sector Outperform |
| Jan-21-22 | Resumed | Cantor Fitzgerald | Overweight |
| Jan-06-22 | Resumed | Piper Sandler | Neutral |
| Oct-15-21 | Resumed | Cowen | Market Perform |
| Sep-27-21 | Initiated | Canaccord Genuity | Buy |
| Feb-11-21 | Upgrade | Piper Sandler | Neutral → Overweight |
| Nov-03-20 | Downgrade | Piper Sandler | Overweight → Neutral |
| Oct-02-20 | Upgrade | JP Morgan | Neutral → Overweight |
| Sep-09-20 | Initiated | Morgan Stanley | Equal-Weight |
| Jun-02-20 | Resumed | Cantor Fitzgerald | Overweight |
| Mar-09-20 | Resumed | Cantor Fitzgerald | Overweight |
| Oct-15-19 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Apr-02-19 | Downgrade | Stephens | Overweight → Equal-Weight |
| Oct-19-18 | Initiated | Cowen | Outperform |
| Nov-03-17 | Downgrade | First Analysis Sec | Overweight → Equal-Weight |
| Sep-28-17 | Downgrade | CL King | Buy → Neutral |
| Nov-03-16 | Reiterated | Cantor Fitzgerald | Buy |
| Jun-27-16 | Initiated | CL King | Buy |
| Apr-15-16 | Initiated | First Analysis Sec | Overweight |
| Feb-04-16 | Downgrade | Piper Jaffray | Overweight → Neutral |
| Jan-04-16 | Reiterated | Cantor Fitzgerald | Buy |
| Oct-23-15 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Aug-27-15 | Initiated | Cantor Fitzgerald | Buy |
| Feb-04-15 | Reiterated | Maxim Group | Buy |
| Sep-26-13 | Reiterated | Maxim Group | Buy |
| Jan-14-13 | Reiterated | Maxim Group | Buy |
View All
Pacific Biosciences Of California Inc Stock (PACB) Latest News
Cathie Wood's ARK Invest ETFs Buy $46.2M in Biotech Stocks, Trim Defense Exposure - AInvest
What’s the profit margin of Pacific Biosciences of California Inc.Gap Down & Expert Verified Movement Alerts - newsyoung.net
Will Pacific Biosciences of California Inc. benefit from seasonalityJuly 2025 Retail & Consistent Profit Focused Trading Strategies - sundaytimes.kr
Pacific Biosciences Of California, Inc. shares fall 1.53% after-hours following Zentek Ltd.'s MD&A release. - AInvest
Published on: 2025-08-15 04:22:23 - thegnnews.com
PacBio (PACB) Shares Skyrocket, What You Need To Know - Yahoo Finance
PacBio’s Path: Upward Surge or Shortlived Spike? - StocksToTrade
Pacific Biosciences Of California, Inc. shares rise 1.65% premarket. - AInvest
Pacific Biosciences of California, Inc. (NASDAQ:PACB) Q2 2025 Earnings Call Transcript - Insider Monkey
The Analyst Verdict: Pacific Biosciences In The Eyes Of 4 Experts - 富途牛牛
PACB Q2 Deep Dive: International Demand, Consumables Growth, and Clinical Adoption Drive Results - Yahoo Finance
PACB Analyst Update: Piper Sandler Raises Price Target by 20% | - GuruFocus
Pacific Biosciences: Piper Sandler Keeps Neutral Rating, Raises PT to $1.5 - AInvest
Pacific Biosciences of California, Inc. (NASDAQ:PACB) Just Released Its Second-Quarter Results And Analysts Are Updating Their Estimates - 富途牛牛
Pacific Biosciences of California Earnings: Analysts Boost Forecasts for 2025 - AInvest
Pacific Biosciences of California, Inc. (NASDAQ:PACB) Just Released Its Second-Quarter Earnings: Here's What Analysts Think - uk.finance.yahoo.com
Pacific Biosciences of California (PACB) Reports Q2 Loss, Beats Revenue Estimates - MSN
Pacific Biosciences Q2 2025 Revenue Surpasses Analyst Estimate at $39.8 Million, GAAP Net Loss Narrows to $0.14 - AInvest
PacBio Reports Q2 EPS, Revenue Growth, and Positive Cash Flow - AInvest
Pacific Biosciences Receives Buy Rating from Bernstein, Maintains $1.70 Price Target - AInvest
Pacific Biosciences shares rise 3.57% intraday after reporting smaller-than-expected Q2 loss and positive trial data. - AInvest
PacBio (PACB) Stock Trades Up, Here Is Why - Yahoo Finance
Bernstein Maintains Pacific Biosciences of California(PACB.US) With Buy Rating, Raises Target Price to $1.7 - 富途牛牛
PacBio Stock Up on Q2 Earnings & Revenue Beat Estimates, Margin Rises - Yahoo Finance
Pacific Biosciences stock price target raised by Bernstein to $1.70 on clinical uptake - Investing.com Canada
Powered by PacBio: Selected publications from July 2025 - PacBio
Earnings call transcript: Pacific Biosciences Q2 2025 beats revenue expectations, stock surges - Investing.com Canada
Pacific Biosciences: Q2 Earnings Snapshot - Connecticut Post
Pacific Biosciences of California Q2 2025 Earnings Call Transcript - MarketBeat
Pacific Biosciences shares rise 11.11% premarket after reporting smaller-than-expected Q2 loss and positive trial data. - AInvest
PacBio Narrowed Losses As New Tech And China Deal Paid Off - Finimize
Pacific Biosciences of California Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Pacific Biosciences (PACB) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates - sharewise.com
PacBio (NASDAQ:PACB) Delivers Strong Q2 Numbers, Stock Soars - TradingView
Pacific Biosciences Q2 Earnings: Smaller Loss Than Expected - AInvest
PacBio Announces Second Quarter 2025 Financial Results - GlobeNewswire
Pacific Biosciences Q2 Earnings Exceed Expectations with $39.8M Revenue and -$0.13 Non-GAAP EPS - AInvest
PacBio to Present at Upcoming Investor Conferences - 富途牛牛
PacBio to Present at Upcoming Investor Conferences in August and September 2025 - Quiver Quantitative
PacBio (PACB) Q2 Earnings Report Preview: What To Look For - Yahoo Finance
Pacific Biosciences of California Inc expected to post a loss of 17 cents a shareEarnings Preview - TradingView
Will Pacific Biosciences of California Inc. Reverse From Oversold ConditionsChart Driven High Reward Trading Setup Presented - beatles.ru
Stay Ahead of the Game With Pacific Biosciences (PACB) Q2 Earnings: Wall Street's Insights on Key Metrics - Yahoo Finance
PacBio and Collaborators Release Landmark Platinum Pedigree Dataset, Enhancing Genomic Variant Accuracy by 34% With AI Integration - Quiver Quantitative
Nature Methods Paper Leverages PacBio Sequencing Technology to Develop the Platinum Pedigree Benchmark, a New Standard for Accurate Characterization of Variation in the Human Genome that Improves Training for AI Models - Yahoo Finance
How strong is Pacific Biosciences of California Inc. company’s balance sheetGet expert advice on portfolio optimization - Jammu Links News
When is Pacific Biosciences of California Inc. stock expected to show significant growthOutstanding capital returns - Jammu Links News
What catalysts could drive Pacific Biosciences of California Inc. stock higher in 2025Invest smarter with expert trading signals - Jammu Links News
Should I hold or sell Pacific Biosciences of California Inc. stock in 2025Superior risk-adjusted returns - Jammu Links News
How does Pacific Biosciences of California Inc. generate profit in a changing economyAchieve rapid wealth accumulation with smart picks - Jammu Links News
Pacific Biosciences Of California Inc Stock (PACB) Financials Data
Revenue
Net Income
Cash Flow
EPS
Pacific Biosciences Of California Inc Stock (PACB) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Farmer Michele | See Remarks |
May 19 '25 |
Sale |
1.00 |
5,195 |
5,200 |
269,259 |
| HENRY CHRISTIAN O | See Remarks |
Mar 03 '25 |
Sale |
1.41 |
12,497 |
17,583 |
2,225,357 |
| Van Oene Mark | See Remarks |
Mar 03 '25 |
Sale |
1.41 |
6,486 |
9,126 |
1,497,695 |
| Farmer Michele | See Remarks |
Mar 03 '25 |
Sale |
1.41 |
2,973 |
4,183 |
184,619 |
1.37%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):